35 articles for DS Karanewsky
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
26
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase

Genomics Institute of The Novartis Research Foundation
10
Dual metalloprotease inhibitors. III. utilization of bicyclic and monocyclic diazepinone based mercaptoacetyls

TBA
12
Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls

TBA
15
Dual metalloprotease inhibitors. I. constrained peptidomimetics of mercaptoacyl dipeptides

TBA
19
Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.

TBA
37
Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor.

Genomics Institute of The Novartis Research Foundation
25
Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.

Ligand Pharmaceuticals
17
Discovery of nonsteroidal glucocorticoid receptor ligands based on 6-indole-1,2,3,4-tetrahydroquinolines.

Ligand Pharmaceuticals
5
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.

Squibb Institute For Medical Research
136
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.

The Genomics Institute of The Novartis Research Foundation
56
Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.

Genomics Institute of The Novartis Research Foundation
13
Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.

Genomics Institute of The Novartis Research Foundation
22
Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold.

Genomics Institute of The Novartis Research Foundation
30
Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.

Ligand Pharmaceuticals
33
5(Z)-benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulators.

Ligand Pharmaceuticals
26
Structure-activity relationships and sub-type selectivity in an oxabicyclic estrogen receptor alpha/beta agonist scaffold.

Ligand Pharmaceuticals
3
Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.

Idun Pharmaceuticals
19
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.

Ligand Pharmaceuticals
18
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.

Ligand Pharmaceuticals
3
Structure-activity relationships within a series of caspase inhibitors: effect of leaving group modifications.

Idun Pharmaceuticals
17
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.

Ligand Pharmaceuticals
18
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.

Ligand Pharmaceuticals
20
Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization.

Idun Pharmaceuticals
51
Acyl dipeptides as reversible caspase inhibitors. Part 1: initial lead optimization.

Idun Pharmaceuticals
10
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.

Eli Lilly
8
Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.

The Bristol-Myers Squibb Pharmaceutical Research Institute
15
Conformationally constrained inhibitors of caspase-1 (interleukin-1 beta converting enzyme) and of the human CED-3 homologue caspase-3 (CPP32, apopain).

Idun Pharmaceuticals
56
Discovery and Development of S6821 and S7958 as Potent TAS2R8 Antagonists.

Firmenich
175
Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors

Lilac Therapeutics
174
Inhibitors of lysine specific demethylase-1

Celgene Quanticel Research
70
Chemical compounds

AstraZeneca
9
[7,6]-fused bicyclic antidiabetic compounds

Merck Sharp & Dohme
97
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes

Janssen Pharmaceutica
19
KCC2 POTENTIATORS AND USES THEREOF

Axonis Therapeutics
29
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.

AstraZeneca